(Q36660355)

15 August 2017

1 reference

title

Olsalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in inflammatory bowel disease (English)

1 reference

inflammatory bowel diseases

15 August 2017

main subject

0 references

olsalazine sodium

1 reference

ChEBI release 2020-05-28

1 reference

1 reference

Wadworth AN

1

1 reference

15 August 2017

Fitton A

series ordinal

2

1 reference

15 August 2017

publication date

1 April 1991

1 reference

15 August 2017

1 reference

15 August 2017

volume

41

1 reference

15 August 2017

issue

4

1 reference

15 August 2017

page(s)

647-664

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-199141040-00009

15 August 2017

exact match

0 references

cites work

Disposition of 5-aminosalicylic acid from 5-aminosalicylic acid-delivering drugs during accelerated intestinal transit in healthy volunteers

1 reference

12 December 2020

Cytoprotection against neutrophil derived hypochlorous acid: a potential mechanism for the therapeutic action of 5-aminosalicylic acid in ulcerative colitis

1 reference

12 December 2020

Effects of topical 5-aminosalicylic acid and prednisolone on prostaglandin E2 and leukotriene B4 levels determined by equilibrium in vivo dialysis of rectum in relapsing ulcerative colitis

1 reference

12 December 2020

Effect of disodium azodisalicylate on electrolyte transport in rabbit ileum and colon in vitro. Comparison with sulfasalazine and 5-aminosalicylic acid

1 reference

12 December 2020

Olsalazine in the treatment of mild to moderate ulcerative colitis: a randomized, placebo-controlled, double-blind, clinical trial

1 reference

12 December 2020

Olsalazine in active ulcerative colitis: dose finding study in Japan

1 reference

12 December 2020

Olsalazine-O-sulphate: an acid labile metabolite of olsalazine

1 reference

12 December 2020

Induction of and adaptation to olsalazine induced intestinal volume load.

1 reference

12 December 2020

Effect of azodisal sodium on the distribution of a transit marker in the small bowel of the fasted rat.

1 reference

12 December 2020

Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion

1 reference

12 December 2020

Biliary excretion of olsalazine sodium in humans

1 reference

12 December 2020

Pancreatitis induced by disodium azodisalicylate

1 reference

12 December 2020

Double-blind placebo-controlled study of olsalazine in the treatment of ulcerative colitis

1 reference

12 December 2020

Possible mode of action of 5-aminosalicylic acid

1 reference

12 December 2020

Intraluminal colonic levels of arachidonic acid metabolites in ulcerative colitis

1 reference

12 December 2020

Inhibition of intestinal macrophage chemotaxis to leukotriene B4 by sulphasalazine, olsalazine, and 5-aminosalicylic acid

1 reference

12 December 2020

Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease

1 reference

12 December 2020

Secretory effect of azodisalicylate (azodisal sodium) on the short circuited mucosa of the rat ileum in vitro

1 reference

12 December 2020

Distribution and metabolism in healthy volunteers of disodium azodisalicylate, a potential therapeutic agent for ulcerative colitis

1 reference

12 December 2020

Newer 5-aminosalicylic acid based drugs in chronic inflammatory bowel disease

1 reference

12 December 2020

Clinical tolerance of olsalazine.

1 reference

12 December 2020

Effect of olsalazine sodium on migrating motor complexes in the upper small bowel of human volunteers.

1 reference

12 December 2020

Inhibition of 5-lipoxygenase pathway of arachidonic acid metabolism in human neutrophils by sulfasalazine and 5-aminosalicylic acid.

1 reference

12 December 2020

Olsalazine or sulphasalazine in first attacks of ulcerative colitis? A double blind study

1 reference

12 December 2020

Effects of sulphasalazine and disodium azodisalicylate on colonic PGE2 concentrations determined by equilibrium in vivo dialysis of faeces in patients with ulcerative colitis and healthy controls

1 reference

12 December 2020

Clinical evidence supporting the radical scavenger mechanism of 5-aminosalicylic acid

1 reference

12 December 2020

Olsalazine does not increase the bile acid losses in subjects with a permanent ileostomy

1 reference

12 December 2020

Olsalazine in the treatment of ulcerative colitis among patients intolerant of sulphasalazine: a prospective, randomized, placebo-controlled, double-blind, dose-ranging clinical trial

1 reference

12 December 2020

Double-blind comparison of olsalazine and sulphasalazine in active ulcerative colitis

1 reference

12 December 2020

Colonic azodisalicylate metabolism determined by in vivo dialysis in healthy volunteers and patients with ulcerative colitis

1 reference

12 December 2020

Olsalazine in active ulcerative colitis

1 reference

12 December 2020

Effects of olsalazine in the jejunum of the rat.

1 reference

12 December 2020

Controlled trial comparing olsalazine and sulphasalazine for the maintenance treatment of ulcerative colitis

1 reference

12 December 2020

Soybean lipoxygenase inhibition: studies with the sulphasalazine metabolites N-acetylaminosalicylic acid, 5-aminosalicylic acid and sulphapyridine

1 reference

12 December 2020

Oxygen-derived free radicals in postischemic tissue injury

1 reference

12 December 2020

Azodisalicylate (Dipentum)-induced hepatitis?

1 reference

12 December 2020

In vitro effects of sulphasalazine, azodisal sodium, and their metabolites on Clostridium difficile and some other faecal bacteria

1 reference

12 December 2020

Effect of 5-aminosalicylic acid (5-ASA) and other salicylates on short-chain fat metabolism in the colonic mucosa. Pharmacological implications for ulcerative colitis

1 reference

12 December 2020

Olsalazine in the treatment of active ulcerative colitis: a placebo controlled clinical trial and assessment of drug disposition

1 reference

12 December 2020

In vivo profiles of eicosanoids in ulcerative colitis, Crohn's colitis, and Clostridium difficile colitis

1 reference

12 December 2020

Clinical experience of the tolerance of mesalazine and olsalazine in patients intolerant of sulphasalazine

1 reference

12 December 2020

Drug treatment and formation of eicosanoids in patients with chronic inflammatory bowel disease.

1 reference

12 December 2020

Treatment of ulcerative colitis with olsalazine and sulphasalazine: efficacy and side-effects

1 reference

12 December 2020

Disposition of 5-aminosalicylic acid by 5-aminosalicylic acid-delivering compounds

1 reference

12 December 2020

Azodisal sodium in the treatment of ulcerative colitis. A study of tolerance and relapse-prevention properties

1 reference

12 December 2020

Azodisalicylate (azodisal sodium) causes intestinal secretion. Comparative study of the effect of azodisalicylate, sulfasalazine, 5-aminosalicylic acid and sulfapyridine on the water and electrolyte transfer and the morphology of the rat ileum and c

1 reference

12 December 2020

Absorption and excretion of azodisal sodium and its metabolites in man after rectal administration of a single 2-g dose

1 reference

12 December 2020

An experiment to determine the active therapeutic moiety of sulphasalazine

1 reference

12 December 2020

Effect of sulphasalazine and its active metabolite, 5-amino-salicylic acid, on toxic oxygen metabolite production by neutrophils

1 reference

12 December 2020

5-Aminosalicylic acid protects against ischemia/reperfusion-induced gastric bleeding in the rat.

1 reference

12 December 2020

Studies on the acetylating capacity of human colonic epithelial cells for 5-aminosalicylic acid

1 reference

12 December 2020

Scavenger effect of sulphasalazine (SASP), 5-aminosalicylic acid (5-ASA), and olsalazine (OAZ)

1 reference

12 December 2020

Disposition of disodium azodisalicylate in healthy subjects. A possible new drug for inflammatory bowel disease

1 reference

12 December 2020

Effect of azodisal sodium and sulphasalazine on ileostomy output of fluid and PGE2 and PGF2 alpha in subjects with a permanent ileostomy

1 reference

12 December 2020

Crohn's disease, sulfasalazine, and mycobacteria

1 reference

12 December 2020

Use of colonic eicosanoid concentrations as predictors of relapse in ulcerative colitis: double blind placebo controlled study on sulphasalazine maintenance treatment

1 reference

12 December 2020

Mesalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in chronic inflammatory bowel disease

1 reference

12 December 2020

Long-term treatment with olsalazine for ulcerative colitis: safety and relapse prevention: a follow-up study

1 reference

12 December 2020

Longterm olsalazine treatment: pharmacokinetics, tolerance and effects on local eicosanoid formation in ulcerative colitis and Crohn's colitis

1 reference

12 December 2020

Rectal mucosal prostaglandin E2 release and its relation to disease activity, electrical potential difference, and treatment in ulcerative colitis

1 reference

12 December 2020

Absorption and excretion of a single 1-g dose of azodisal sodium in subjects with ileostomy

1 reference

12 December 2020

4-Aminosalicylic acid, in contrast to 5-aminosalicylic acid, has no effect on arachidonic acid metabolism in human neutrophils, or on the free radical 1,1-diphenyl-2-picrylhydrazyl

1 reference

12 December 2020

The prophylactic effect of 5-aminosalicylic acid and salazosulphapyridine on degraded-carrageenan-induced colitis in guinea pigs.

1 reference

12 December 2020

Colonic prostaglandin E2 levels and olsalazine metabolism in relapsing ulcerative colitis: implications for controlled trials in the long term

1 reference

12 December 2020

The pharmacokinetics of olsalazine sodium in healthy volunteers after a single i.v. dose and after oral doses with and without food.

1 reference

12 December 2020

Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

1 reference

12 December 2020

10.2165/00003495-199141040-00009

Identifiers

DOI

1 reference

Dimensions Publication ID

15 August 2017

1018852871

0 references

1 reference